Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: An important limiting factor influencing treatment efficacy of neuroendocrine tumors (NETs) with somatostatin analogs (SSA) is the availability of somatostatin receptors (SSTR) on NETs. While downregulation or altered pattern of SSTR expression are important considerations, receptor internalization/desensitization by β-arrestins may be a crucial contributing factor. Interestingly, our previous study showed a preferential higher expression of β-arrestin 1 (ARRB1), in gastroenteropancreatic NETS (GEP-NETs) compared to pituitary adenomas.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Iyer A
Authors: Iyer A, Vriens J, Dogan-Oruç F, van Koetsveld P, Hofland L,
Keywords: β-arrestin 1, CRISPR-Cas9, BON-1, knock-out, SSTR, SSA, Pan-NET,
#2962 90Y- and/or 177Lu-DOTATOC Re-Challenge in Patients with Progressive Neuroendocrine Tumors
Introduction: Most patients treated with PRRT will eventually progress. Previous studies indicated that repeated PRRT is feasible and promising.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Aberle S
Authors: Aberle S, Benz M, Grokovski R, Christ E, Nicolas G,
Keywords: PRRT, Re-challenge, 90Y-DOTATOC, 177Lu-DOTATOC, neuroendocrine tumor,
Introduction: Preclinical studies have suggested that metformin has antitumor effects, likely due to blockage of mTOR pathway through AMPK and decreased insulin levels. A retrospective study showed that metformin combined with everolimus to treat related hyperglycemia offered longer progression-free survival (PFS) in patients (pts) with pancreatic neuroendocrine tumors (NET).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Glasberg J
Authors: Glasberg J, Talans A, Lopez R, Recchimuzzi D, Riechelmann R,
Keywords: neuroendocrine tumors, metformin, clinical trial,
Introduction: The driving genetic alteration leading to neuroendocrine tumor (NET) development has been reported for primary tumors of pancreatic origin, but not for metastases. Moreover, even for primary tumor a significant “dark matter” remains to be explored.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Tirosh A
Authors: Tirosh A, Killian J, Zhu Y, Neychev V, Meltzer P,
Keywords: GEP-NET, Driver mutation, Copy-number, Metastases,
Introduction: CLARINET demonstrated the antitumour effect of LAN 120mg/28 days (standard interval) in metastatic gastroenteropancreatic NETs. If disease progresses (PD) on this dose, aggressive treatments (eg targeted therapies) are usually offered.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Pavel M, Dromain C, Majdi A, Houchard A,
Keywords: Lanreotide, dosing interval,